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Metabolic Engineering of 




Saccharomyces cerevisiae is an important and popular host for production of 
value-added molecules such as pharmaceutical ingredients, therapeutic proteins, 
chemicals, biofuels and enzymes. S. cerevisiae, the baker’s yeast, is the most used 
yeast model as there is an abundance of knowledge on its genetics, physiology and 
biochemistry, and also it has numerous applications in genetic engineering and 
fermentation technologies. There has been an increasing interest in developing 
and improving yeast strains for industrial biotechnology. Metabolic engineering is 
a tool to develop industrial strains by manipulating yeast metabolism to enhance 
the production of value-added molecules. This chapter reviews the metabolic 
engineering strategies for developing industrial yeast strains for biotechnologi-
cal applications and highlights recent advances in this field such as the use of 
CRISPR/Cas9.
Keywords: metabolic engineering, evolutionary engineering, Saccharomyces 
cerevisiae, biopharmaceuticals, industrial biotechnology, CRISPR-Cas9
1. Introduction
The term “metabolic engineering” was introduced by [1] into the science. 
Metabolic engineering is defined as “the improvement of cellular activities by 
manipulation of enzymatic, transport and regulatory function of the cell with the 
use of recombinant DNA technology” [1].
Metabolic engineering aims to manipulate genetic information of the strain 
and “improve the cellular activities” of the strain [1]. Stress tolerance of yeast is 
important and needs to be improved in industrial processes. Heterologous path-
ways and metabolic engineering cause stress on the yeast strain. The compound of 
interest can be toxic to the host strain and heterologous pathways are more sensitive 
than endogenous pathways. During the industrial processes, high salt, high tem-
perature, high ethanol, acids and inhibitors can cause stress and affect industrial 
processes [2].
Metabolic engineering makes stress tolerance possible by improvement and 
modification of cellular functions of yeast. [3]. Metabolic engineering can be 




1.1 Rational metabolic engineering
Rational metabolic engineering is the fundamental type of metabolic engineer-
ing. It focuses on the engineering of proteins and enzymes based on the knowledge 
of pathways and their regulation [4]. Protein activities are optimized to design a 
desired strain based on the protein and host information [5].
Application of systems biology helps to obtain protein and host information and 
also to model the system. In rational metabolic engineering, a mathematical model 
is needed to predict the strategies that can improve the strain. [6].
1.2 Evolutionary engineering
Evolutionary engineering is the method for strain improvement by mutagenesis 
or gene recombination and shuffling, after which a cell with the desired phenotype 
can be obtained. In other words, multiple cycles of random genetic perturbation are 
performed and the strains are selected. These two events are sequentially performed 
[7, 8]. Evolutionary engineering is a method that improves the strain by mimicking 
the evolutionary process [9, 10]. Aim of the evolutionary engineering is to obtain 
desired phenotypes by mimicking the natural evolutionary process. The evolution-
ary process is achieved by appropriate selective pressure. Their molecular mecha-
nism is then studied. Industrially important traits such as stress tolerance, product 
formation and substrate utilization are improved by evolutionary engineering. 
Through evolutionary engineering, Saccharomyces cerevisiae can be made to become 
resistant to multiple types of stress. Evolutionary engineering is used to improve the 
stress resistance of S.cerevisiae, such as ethanol resistance [11], salt resistance [12], 
freeze resistance [13].
In this method, the best screening method must be found for the stress of 
interest. Genetic modifications are random. Strains evolved through evolutionary 
engineering can provide genetic information for the improved strain and this infor-
mation can be used for inverse metabolic engineering [7, 14] or random methods 
for deletion or overexpression of genes [15] or to introduce random mutations. It 
accumulates random mutations in the genome of the host. It is not easy to deter-
mine which genetic modification causes the strain improvement. [16].
While developing a microbial strain, toxicity and tolerance of bioproduct, 
cell growth during fermentation and also downstream processes are considered. 
Optimization of these factors and cell performance is a difficult task due to the lack 
of knowledge on the relationship between genotype and phenotype.
Evolutionary engineering can be classified into two categories: adaptive labora-
tory evolution (ALE) and directed evolution [17].
1.2.1 Adaptive laboratory evolution
The physical and chemical mutagens and error prone-PCR (ep-PCR) are 
the methods of traditional random mutagenesis used in adaptive laboratory 
evolution.
In adaptive laboratory evolution, after strains are cultured under selected pres-
sure for long periods, strains with beneficial mutations are screened and selected. 
Cells with beneficial mutations outgrow the other strains during culturing under 
the selection pressure. Adaptive laboratory evolution (ALE) is commonly used to 
improve product titer, carbon source utilization, increase tolerance, and optimize 
cell growth and identify unknown biological mechanisms [17, 18].
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1.2.2 Directed evolution
In directed evolution, the desired selection pressure is applied to develop 
enzymes with new or improved properties. Protein engineering uses directed 
evolution to enhance activity of the enzymes. Directed evolution focuses on a gene 
encoding a protein or enzymes. ALE focuses on the entire organism and exhibits 
spontaneous mutations. Genetic diversity can be generated at a single gene, at 
pathways or for the whole genome [17, 19].
Oligo mediated targeted mutation generation such as multiplex automated 
genome engineering (MAGE), a modified method of MAGE called yeast oligo-
mediated genome engineering (YOGE) and RNAi-assisted genome evolution 
(RAGE) can be used for directed evolution [20, 21].
1.3 Inverse metabolic engineering
Inverse metabolic engineering has three important steps to be applied to the 
strains. In the first step, the desired phenotype is identified, constructed and 
calculated. In the second step, the phenotype of interest is characterized according 
to genetic or environmental factors. In the third step, the phenotype of another 
strain or organism is translated to our strain by directed genetic manipulations or 
environmental manipulations [4]. Inverse metabolic engineering benefits from 
phenotypic differences. The host strain is exposed to different environmental 
conditions. Then, the trait of the organism which makes it resistant is investigated; 
after which, genetic basis of this trait is identified. Transcriptomics, proteomics 
and metabolomics is used to identify the basis of the trait [14, 22]. Xylose assimila-
tion is improved in recombinant Saccharomyces cerevisiae by inverse metabolic 
engineering. A genomic fragment library from Pichia stipitis was introduced into 
S.cerevisiae expressing XYL1 and XYL2. Then, the transformants with high xylose 
growth rate were chosen. After sequencing, XYL3 is the responsible gene for 
high xylose growth rate [23]. The concept of reverse metabolic engineering has 
advantages. There is no information about the proteins and their regulation in the 
pathway. Their regulation, industrial strains and actual production conditions can 
be directly utilized to identify key genetic players. Homologous genes are responsi-
ble for the final strain development. New genetic targets can be discovered. When 
heterologous genes are needed to be added, it is better to use rational metabolic 
engineering. Despite the advantages of inverse metabolic engineering, strain 
development will be more successful when all metabolic engineering methods are 
used [9].
In theory, microorganisms can produce all the metabolites that they produce in 
their cells, however they produce low levels of these products. Metabolic engineer-
ing has made it possible to induce the production of chemicals and proteins in 
higher volume. Titer, yield and productivity of the products is improved by meta-
bolic engineering. The improvement of results for the product of interest contrib-
uted to the development of the strategies in metabolic engineering. To develop and 
improve industrial strains, the strategies with the help of metabolic engineering, 
systems biology and synthetic biology are used [24–27].
There are metabolic engineering tools that help us to make industrial strains. 
Using metabolic engineering, novel metabolic pathways can be constructed, new 
metabolic engineering targets can be identified, gene expression can be controlled 
and tolerance to stress can be increased. These tools and strategies can be used 
not only for strain development but it will be helpful for fermentation strategies, 
Saccharomyces
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as well. Systems biology, synthetic biology and metabolic engineering help the 
industry develop resistant and efficient strains [27].
2. Systems biology and metabolic engineering
Systems biology focuses on interpreting cellular networks via computational 
simulations and omics data analysis [28].
Metabolic engineering research whereby an engineered strain produces chemi-
cals, proteins, biofuel or a material that has economical value. It is important to 
scale up the strains for industry. Metabolic engineering is successful in developing 
a strain that overproduces the product of interest at the lab-scale. However, devel-
oping an industrial strain can produce bioproducts is challenging and takes time, 
effort and money. A combination of metabolic engineering and systems biology is 
systems metabolic engineering [24, 29].
Traditional metabolic engineering approaches are integrated into systems biol-
ogy and synthetic biology. Systems biology focuses on genome-scale computational 
simulation and omics analysis and synthetic biology focuses on the tools at the 
molecular level and pathways. Genome engineering and evolutionary engineering 
focuses on stress tolerance [28].
The combination of metabolic engineering and systems biology is called 
system metabolic engineering. It focuses on cell growth and target chemical 
production to accomplish the desired phenotype. Omics technology can be used 
for engineered strains. Sequencing all genomes is helpful to understand the 
differences between strains, however the difference is large. It will be difficult 
to find the real reason for the phenotype and the cost will also be high. The 
analysis of transcriptome, proteome, metabolome and fluxome offer informa-
tion about the differences between strains because they are closely related to 
the phenotype [9]. The last step of inverse metabolic engineering is “omics” 
technologies. Here, “omics” technologies can find the differences at the gene 
level. The control of the target genes can be done by deleting or overexpressing 
the target genes in the strain. The result of this experiment will determine if 
this genetic modification will give the desired phenotype. The aim of the omics 
technologies are the gene detection (genomics), mRNA detection (transcrip-
tomics), proteins detection (proteomics) and metabolites detection (metabo-
lomics) in a strain. Omics technologies are genomics (study of an organism’s 
genome, detection of genes), transcriptomics (mRNA detection, gene expres-
sion microarrays), proteomics (detection of protein to understand pathways 
and networks) and metabolomics (detection of global metabolite profiles in a 
system) and fluxomics (detection of metabolic fluxes) [30]. Genomics is the 
study of the whole genome of an organism. The study of chemical process, 
metabolites and the products of metabolism in a cell is called metabolomics. 
Analyses of omics can provide information on cellular and metabolic charac-
teristics at the industrial strains. Omics data can give information on which 
genes or pathways are enhanced for the production of the bioproduct of interest 
[27]. Multi-omics data is applied to investigate the characteristics of the strain. 
Multi-omics analyses are done to select genetically engineered strains and the 
best strain for metabolic engineering.
Genome-scale metabolic models (GEMs) simulate the gene-protein-reaction 
(GPR) relationships for all the genes in an organism and help the researchers to 
predict metabolic response and fluxes for various systems-level metabolic stud-
ies. Genome-scale metabolic model (GEM) helps to develop strains to produce 
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chemicals and drugs. GEM helps to predict enzyme functions, interactions among 
cells or organisms and understand the human diseases [31].
After the whole genome sequencing, genome-scale metabolic models have 
helped to predict cellular metabolisms and function and showed a way to identify 
the targets to increase the compound of interest. The first GEM for Haemophilus 
influenzae was established in 1999. MOMA is one of the widely used algorithms to 
identify the targets which helped to increase the production of the compound of 
interest. OptKnock is another program used for metabolic engineering [27].
The synthetic pathways for the compound of interest can be predicted by path-
way prediction algorithms. Biochemical network integrated computational explorer 
(BNICE), RetroPath, GEM-Path, OptStrain and DESHARKY are the examples of 
pathway prediction algorithms [27].
Stable or enhanced enzymes are needed for the processes of the production 
of the chemicals. Computational protein design tools design new or improved 
enzymes by identifying core parts of protein structure and target sites for 
 engineering [27].
3. Synthetic biology and metabolic engineering
Synthetic biology is the combination of engineering and biology. It can 
redesign or engineer biological systems [32]. In synthetic biology, biomolecular 
components, networks and pathways are designed and then, used to reprogram 
organisms [33]. Synthetic biology focuses on DNA synthesis, design and con-
struction of novel metabolic pathways [27]. After construction of the synthetic 
pathways, the metabolic pathways should be optimized and maximized to 
improve the yield of the product of interest. The target site of metabolic path-
ways was chosen by the help of genome-scale metabolic models (GEMs) and 
multi-omics analyses. The high performing, resistant and efficient strains will 
be constructed according to synthetic biology tools [17, 27]. Optimization of the 
pathway needs to done after the synthetic pathway is constructed. Pathway opti-
mization can be controlled by gene expression. Gene expression can be modulated 
by gene expression components or regulatory RNAs. Any modulation on the 3′ or 
5′ untranslated region (UTR), transcription factor, promoter, ribosomal binding 
site or terminator can control gene expression. RNAi will be effective in control-
ling genes [34]. RNAi is a gene knockdown system in eukaryotes and an important 
method for metabolic engineering. RNA-induced silencing complex (RISC) pro-
tein reduces mRNA levels via a small interfering RNA (siRNA). Double stranded 
RNA is degraded to siRNA by a protein called dicer. Argonaute recognizes small 
guide RNAs which will recognize and degrade mRNAs of the target gene. RNAi 
has been widely used for metabolic engineering in eukaryotic organisms. In prior 
study [34], hairpin RNA expression cassettes are constructed to improve itaconic 
acid production.
The disadvantage of metabolic engineering is whole-genome sequencing to iden-
tify the trait. Clustered regularly interspaced short palindromic repeats (CRISPR-
Cas9) has led to a new era for genome engineering [35]. CRISPR-Cas9 made a huge 
impact on the advancement of engineering of microbial cell factories. Endogenous 
homology-directed repair (HDR) or non- homologous end joining (NHEJ) are DNA 
repair pathways and used to insert or delete genes. However, their efficiency is low 
for metabolic engineering of microbial organism [36, 37, 38].
Endonucleases are used to double strand break induction and increase the 
recombination efficiencies [39]. The disadvantage of endonucleases is that they 
Saccharomyces
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are not a successful strategy for large genomes. Transcription-activator nucleases 
TALENs and Zinc-finger nucleases (ZFNs) are advantageous for sequence specific-
ity [38]. TALENs are focused on a smaller size of the genome. The CRISPR-Cas9 
system is a defense mechanism that bacteria against viruses. In a class II CRISPR/
Cas system, Cas9 is an endonuclease and introduces a double strand break. Trans-
activating CRISPR RNA (tracrRNA) and CRISPR RNA (crRNA) collectively guide 
Cas9 to the target region. Cas9 cleaves the DNA-strand which is the complementary 
strand of the crRNA-guide sequence. In genome engineering, crRNA and tracrRNA 
are fused and used together.
The CRISPR-Cas system is used for metabolic engineering in S. cerevisiae [40]. 
CRISPR interference (CRISPRi) is a system that is used for gene downregula-
tion. Deactivated Cas9 binds to the target DNA and blocks the transcriptional 
 initiation [41].
4. Biopharmaceuticals and metabolic engineering
Bio-based chemicals’ market size is estimated to reach USD 97.2 billion by 
2023. According to biopharmaceutical market forecast report, the market size 
is 239.8 billion in 2019 and it is estimated to grow at a CAGR of 13.28% during 
period 2020–2025. Biopharmaceuticals represent 25% of commercial drugs 
and about 40% of total pharmaceutical sales [42]. Total biopharmaceutical 
sales are over $275 billion in 2019 and doubled from $125 billion in 2012. Total 
biopharmaceutical sales are growing at 12 percent annually. $200 billion of 
$275 billion are the sales of recombinant proteins. The rest of the sales are 
non-recombinant vaccines as well as blood and plasma products [43]. Sales of 
most biopharmaceuticals have grown significantly versus sales in 2011. The 
top three categories of sales are recombinant proteins, monoclonal antibodies 
and insulin [44]. The USA FDA and European Medicines Agency have stimu-
lated the biopharmaceutical industry to produce more biopharmaceuticals 
[43]. Improvement of human health and life longevity are the benefits of the 
medicine. Biopharmaceuticals play an important role in the treatment of many 
disease [45]. The first biopharmaceutical was the recombinant human insulin 
produced in Escherichia coli. Eli Lilly launched the recombinant human insulin 
to the market in 1982 [46].
Approximately 70% of potential drugs in development are developed for 
diseases such as diabetes, cancer, neurological and immunological diseases. The 
effectiveness of biopharmaceuticals in the treatment of cancer and HIV/AIDS has 
been observed in the last decade. Deaths due to these diseases have decreased with 
the use of biopharmaceuticals. As a result, it has led to an increase in the use of 
biopharmaceuticals in the global market [47].
Therapeutic enzymes, therapeutic proteins, recombinant growth factors, cell 
and gene therapies, recombinant hormone, synthetic immunomodulators, hor-
mones, monoclonal antibodies and vaccines are biopharmaceuticals, and they have 
been extensively used as therapeutic agents [45]. The term “biopharmaceuticals” 
was named in the 1980s. It means pharmaceuticals that are produced using genetic 
engineering [48]. Biopharmaceuticals have many advantages such as targeting 
only specific molecules, having fewer side effects, having high specificity and high 
activity [49]. Biopharmaceuticals are 100–1000 times larger than conventional 
drugs. It is necessary to use microbial and mammalian cells for the production of all 
therapeutic proteins. As a result, biopharmaceuticals are produced in E.coli, yeast 
and mammalian cells [50].
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Yeast has advantages among the cell factories that are used for biopharmaceuti-
cal production. Yeast needs inexpensive medium compared to mammalian cell 
culture. Inexpensive medium for yeast reduces the cost of the biopharmaceutical 
production. Fermentation technologies that are used for yeasts are well-known and 
well-established [51]. However, yeast also has disadvantages in the production of 
therapeutic proteins. The high glycosylation capability of yeast is a disadvantage. If 
the high glycosylation capability is blocked, yeast can produce therapeutic proteins 
with the humanized glycosylation [52].
Cell factories are advantageous due to product quality, scale-up and downstream 
processes. The advantages of producing proteins in mammalian cells are having 
properly-folded protein, good pharmacokinetics and human-like N-glycosylation. 
However, mammalian cells are sensitive to bioprocessing. and the growth medium 
of mammalian cells are expensive [53]. The first human insulin is produced in 
E.coli. Protein production in E.coli is advantageous due the use of and inexpensive 
medium, fast growth time, high cell density culture, easy transformation and 
fast protein production rate. The disadvantage of protein production in E.coli is 
incorrect folding, low solubility and secretion of the protein. S.cerevisiae has good 
properties such as proper folding, easy culture growth and correct post-transla-
tional modifications. Secretion of the product to an extracellular medium is possible 
and this makes the protein purification easier. S. cerevisiae is also free of pathogens. 
S.cerevisiae is the most commonly used yeast strain for recombinant protein pro-
duction. S.cerevisiae can be defined as predominantly unicellular however, many 
yeasts have both unicellular and multicellular lifestyles [54]. S.cerevisiae is used as a 
model for diseases. S.cerevisiae was the first eukaryotic organism to be fully genome 
sequenced [55]. S.cerevisiae has tolerance to chemical and physical stresses and that 
makes it a good model organism protein production in the industry [54].
Bioproduct process contains four stages: (1) first upstream process, (2) second 
upstream process, (3) midstream process and (4) downstream process. Fermentable 
carbohydrates are converted in the first upstream processes. A high-performance 
strain is developed in the second upstream process. In the midstream process, the 
strain is grown, and it produces the product of interest. The desired product is puri-
fied in the downstream process. Microorganisms should be optimized to produce 
the chemical or material of interest efficiently. The optimization and modifications 
can be applied on the microorganisms by metabolic engineering [17].
Metabolic engineering uses synthetic biology, systems biology, and evolutionary 
engineering to develop microorganisms. Metabolic engineering develops highly 
efficient microorganism strains to produce important products such as bioproducts, 
bulk chemicals, materials, natural products, fine chemicals, and polymers. Target 
products should be selected first. Biofuels, bulk chemicals, polymers, fine chemicals 
(including drugs), materials and natural products are bioproducts. Bulk chemicals 
are chemicals with low price and produced in large quantities. Fine chemicals are 
more expensive than bulk chemicals and are produced in small quantities.
Traditional petroleum-based plastics are produced from fossil fuels and are 
unsustainable; thus, bioplastics have become popular [56]. Bio-based polymers 
are polymers that can replace petroleum-based plastics. Polyhydroxy-acids (PHA) 
are biodegradable natural polyesters that are produced in microorganisms and 
have biodegradability and biocompatibility properties. To produce more PHAs 
and poly (lactic-co-glycolic acid), microorganisms can be engineered by metabolic 
engineering. Biofuels are produced by biological and chemical processes. Fatty acid 
biosynthetic pathways, ethanol pathways, CoA-dependent reverse b-oxidation path-
ways, keto acid pathways and isoprenoid pathways are key pathways for biofuels. 
Bioethanol is one such biofuel that is produced by microorganisms and developed 
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by metabolic engineering. E. coli and Saccharomyces cerevisiae have been used for 
the production of biofuels. The classification of natural products is based on their 
structures. This classification contains alkaloids, terpenoids, phenylpropanoids, 
and polyketides. The source of natural products are natural sources. The cost of 
extracting natural products is high. The extraction of natural products leads to low 
yield. Natural products can be produced by chemical synthetic routes. However, 
production by chemical synthetic routes can generate multistep reactions and 
stereoisomers. Natural product production can be performed by metabolic engi-
neering strategies. Selection of a host strain is based on the product. There are three 
ways to choose the host strain. First, the desired product can be overproduced by the 
host strain. Second, the desired product can be produced with low efficiency. Third, 
the target product is not produced by the host strain. The host strain will be gener-
ated using different metabolic engineering strategies. E. coli and S. cerevisiae are 
popular host strains to produce biodiesel hoewever, the efficiency is low. ‘Generally 
recognized as safe’ (GRAS) microorganisms should be used to produce food and 
pharmaceutical products for the safety issues. Bacillus subtilis and S. cerevisiae are 
well-known GRAS strains [57]. Artemisinic acid is known as an anti-malarial drug 
precursor and is produced in S. cerevisiae by introduction of heterologous pathways. 
Opioids were produced in S. cerevisiae [58]. Systems metabolic engineering can 
enhance the production of recombinant proteins such as artemisinic acid. Some of 
the target pathways are not available in microorganisms. Enzymes and metabolic 
pathways for the desired product should be designed by metabolic engineering. For 
example, lactams cannot be produced by natural pathways, and de novo pathways 
should be designed for lactams. Penicillin is a beta-lactam non-ribosomal peptide. 
Baker’s yeast Saccharomyces cerevisiae can produce and secrete penicillin by meta-
bolic engineering. Five genes in the benzylpenicillin pathway in P. chrysogenum were 
integrated into S. cerevisiae. Bioactive benzylpenicillin is then produced and secreted 
by S. cerevisiae [59].
If natural pathways of the production of the desired product is unknown, 
then GEM-Path, DESHARKY, RetroPath and RetroRules are used as prediction 
algorithm tools for metabolic pathway design. Mutations should be identified 
after these methods. Colorimetric assays, spectrophotometer fluorescence-acti-
vated cell sorting (FACS), or microfluidic sorting devices can be used to identify 
the beneficial mutation in the organism. The pathway should be optimized after 
the metabolic pathway is constructed in the host strain. Genome-scale metabolic 
simulation, plasmids, regulatory RNAs, and genome engineering are used to 
optimize the pathways of the host strain. Recombination-mediated genetic engi-
neering is used to optimize pathways and produce the desired product efficiently. 
RecABCD system-based homologous recombination, the l Red recombination, 
site-specific recombination systems including Cre-lox and flippase-flippase 
recombinase target (Flp-FRT), zinc finger nuclease (ZFN) and CRISPR along 
with CRISPR/Cas are genome engineering tools [57]. The b-amyrin is a pentacy-
clic triterpenoid compound and was produced by S. cerevisiae strain engineered 
by CRISPRi [60].
Scale-up fermentation is an important step for biopharmaceuticals. The strain’s 
growth performance and optimal fermentation conditions have been validated 
for lab-scale fermentation (0.5–30 L). After lab-scale fermentation is approved, 
pilot-scale fermentations (30–3000 L) and large scale production (3000–20,000 L) 
will be performed to see the conditions of the strain and the product of interest. 
Full-scale (20,000–2,000,000 L) production fermentation will be performed for 
the production of biopharmaceuticals. In scale-up fermentation, gradients of feed, 
oxygen concentrations, and maintaining the genomic stability of high-performing 
strains will be a challenge [27].
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5. Conclusions and future perspectives
Metabolic engineering is a successful method to construct efficient microbial 
cell factories. These methods and developments in metabolic engineering make 
S. cerevisiae an efficient and leading host strain for protein production.
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